CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH EARLY COMBINED ESTROGEN AND PROGESTOGEN HORMONE THERAPY FOR POST-MENOPAUSAL WOMEN

Author(s)

Baser O1, Racketa J2, Bushmakin A3, Komm B2, Trocio J4, Xie L51STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Pfizer, Inc., Collegeville, PA, USA, 3Pfizer, Inc., New London, CT, USA, 4Pfizer, Inc., New York, NY, USA, 5STATinMED Research, Ann Arbor, MI, USA

OBJECTIVES: Compare clinical and economic outcomes between post-menopausal women treated with combined estrogen and progestogen hormone therapy (HT) within 1 and 1-2 years after diagnosis. METHODS: A retrospective analysis of women age 45 or older from a large U.S. health plan (April 2002-September 2010) was conducted. The first HT prescription during the identification period (April 2005-September 2008) was identified as the index date. Patients were selected if they initiated HT treatment within 2 years of menopause diagnosis, and had 3 years of continuous health plan enrollment before (pre-period) and 2 years after the index date (post-period). Patients with evidence of post-period pregnancy or pre-period other HT treatment were excluded. Two cohorts were created based on HT initiation date (Cohort A: HT initiated within 1 year of diagnosis; Cohort B: 1-2 years after diagnosis). Propensity score matching (PSM) was used to adjust for baseline differences in age, region, procedure used, comorbidities, and healthcare utilizations during the pre-period. RESULTS: Among 4268 eligible patients, 69.3% (N=2956) were included in Cohort A and 30.7% (N=1871) in Cohort B. After PSM, 1310 patients from each group were matched. Patients prescribed HT within 1 year of menopause diagnosis (Group A) were less likely to have Dual-Energy X-RAY Absorptiometry (DEXA) scans and osteopenia than patients treated between 1-2 years after menopause diagnosis. In addition, patients with earlier treatment showed a higher medication possession ratio (MPR) (0.49 vs. 0.46, p=0.272). Healthcare costs and utilizations remained similar, except patients with early HT treatment had significantly lower emergency room visit rates (22.9% vs. 26.5%, p=0.033) than patients with late HT treatment. CONCLUSIONS: Patients initiating HT within 1 year of menopause diagnosis had fewer comorbidities, directionally higher MPR but not significant, and lower emergency room visit rates than women initiating HT between 1-2 years. Other clinical and economic outcomes were similar.

Conference/Value in Health Info

2012-06, ISPOR 2012, Washington, D.C., USA

Value in Health, Vol. 15, No. 4 (June 2012)

Code

PIH25

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Reproductive and Sexual Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×